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Fat-mass and obesity-associated gene
polymorphisms and weight gain after risperidone
treatment in first episode schizophrenia
Xueqin Song1*†, Lijuan Pang1†, Yufang Feng2, Xiaoduo Fan3, Xue Li1, Wei Zhang1, Jinsong Gao1, Jianjiang Zhang1,
Katlyn Nemani4, Hua Zhang1 and Luxian Lv5,6*
Abstract
Background: Obesity induced by antipsychotics severely increases the risk of many diseases and significantly
reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene
associated with obesity. The relationship between the FTO gene and drug-induced obesity is unclear.
Method: Two hundred and fifty drug naïve, Chinese Han patients with first-episode schizophrenia were enrolled in the
study, and genotyped for four single nucleotide polymorphisms (SNPs rs9939609, rs8050136, rs1421085 and rs9930506)
by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct sequencing. Body
weight and body mass index (BMI) were measured at baseline and six months after risperidone treatment.
Results: At baseline, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609;
body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p’s < 0.05). After 6 months of
risperidone treatment, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609
(p’s <0.01); body weight and BMI of CC homozygotes were lower than those of A allele carriers in rs8050136
(p’s < 0.05); body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p’s < 0.05). After
controlling for age, gender, age of illness onset, disease duration, weight at baseline and education, weight gain of TT
homozygotes at 6 months remained to be lower than those of A allele carriers in rs9939609 (p < 0.01); weight gain of
CC homozygotes at 6 months was lower than those of A allele carriers in rs8050136 (p = 0.01). Stepwise multiple
regression analysis suggested that, among 4 SNPs, rs9939609 was the strongest predictor of weight gain after
6 months of risperidone treatment (p = 0.001).
Conclusions: The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone
treatment in Chinese Han patients with first episode schizophrenia.
Keywords: FTO gene, Weight gain, Schizophrenia, Single nucleotide polymorphism (SNP)
Background
Schizophrenia is a psychiatric disorder that is associated
with impairment in social and occupational functioning
[1]. The use of antipsychotics, especially atypical anti-
psychotics (AAPs), is associated with serious adverse me-
tabolic effects, including weight gain, hyperlipidemia and
glucose intolerance [2], and other [3]. But researches also
suggested that patients taking AAPs do not necessarily de-
velop these adverse effects, suggesting that differential
genetic vulnerability may play a role in antipsychotic-
associated metabolic side effects.
The advent of Genome Wide Association Studies
(GWAS) emerged as a powerful approach to identify
genetic variants associated with common diseases [4].
GWAS has identified a group of loci associated with
obesity [5]. In 2007, Frayling et al. [6] and Scuteri et al.
[7] found a strong association between common single
nucleotide polymorphisms (SNPs) in the first intron of
the fat-mass and obesity-associated (FTO) gene on the
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chromosome 16q12.2, and the risk of obesity. Subse-
quently, many studies have unequivocally replicated the
relationship between FTO gene variants and obesity in
children and adults across different populations [8-15],
including Han Chinese [13,16-18].
The risk of weight gain is variable among different an-
tipsychotics. Olanzapine and clozapine are associated with
the highest risk of weight gain, followed by chloroprom-
zaine, resperidone, and quetiapine [19]. Ziprasidone [20]
and aripiprazole belong to the group with the lowest risk
of weight gain. The rank order of antipsychotics for indu-
cing weight gain is consistent with that of their metabolic
side effects [21], supporting the idea that drug’s risk for
adverse metabolic changes are strongly associated with
its potency for increasing obesity. Risperidone is a com-
mon drug used for schizophrenia treatment in China. As
we known, Variants of FTO gene (such as rs9939609,
rs8050136, rs1421085 and rs9930506) have been consis-
tently reported to be associated with obesity in recent
studies [7,12,22,23], but there have been no studies tested
the potential role in antipsychotic-related obesity except
rs9939609.
The aim of this study was to examine the relationship
between FTO gene polymorphisms (rs9939609, rs8050136,
rs1421085 and rs9930506) and weight gain after 6 months




All subjects provided written informed consent to par-
ticipate in the study, which was approved by the Ethics
Committee of the First Affiliated Hospital of Zhengzhou
University and Henan Mental Hospital. Chinese Han in-
patients between 18 and 50 years old diagnosed with first-
episode schizophrenia (disease duration less than 2 years)
were recruited. Patients were diagnosed with first-episode
schizophrenia according to the criteria of Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), and were never previously treated with anti-
psychotic medications or other psychotropics. The diag-
nosis of schizophrenia was further determined by two
research psychiatrists (X.S. in the First Affiliated Hospital
of Zhengzhou University and L.L. in Henan Mental
Hospital) using the Structured Clinical Interview for
DSM-IV Axis I Disorders. Exclusion criteria included on-
going infections or allergies, history of alcohol or other
substance use, pregnancy, known medical conditions that
might affect metabolism, history of diabetes or lipid dis-
order, use of anti-diabetic or lipid-lowering agents or spe-
cial diets to lower glucose or lipid levels. A complete
medical history was obtained from all subjects. All subjects
were treated in the two hospitals, and underwent daily
physical examination and weekly routine laboratory tests.
After baseline assessment, all patients were treated
with risperidone with the dose ranging from 2 mg to
6 mg per day based on the clinical judgment of treating
psychiatrists. No other medication was allowed during
the study except benzodiazepines for insomnia and anti-
cholinergic agents for dystonia reaction.
Clinical assessment
Anthropometric assessment was performed at baseline
and 6 months after risperidone treatment. Anthropome-
tric measures for each participant were taken after an
overnight fast while the subject wore light clothing and
no shoes. Weight (kg) and height (m) were measured,
and body mass index (BMI) was calculated for all sub-
jects. Symptoms of schizophrenia were assessed using
the Positive and Negative Syndrome Scale (PANSS). The
clinical assessment was administered by two clinical psy-
chiatrists (L.P. in the First Affiliated Hospital of Zhengzhou
University and X.L. in Henan Mental Hospital) who had
attended a training session for the proper use of PANSS
to ensure the consistency and reliability of the ratings
throughout the study. A correlation coefficient above .8
was maintained for the PANSS total score after repeated
assessments.
Genotyping
DNA samples were isolated from peripheral blood using
the QIAamp DNA blood kit (QIAGEN GmbH, Hilden,
Germany). Genotyping of the FTO SNPs (rs9939609,
rs8050136 and rs1421085) was performed using direct
sequencing. The PCR-RFLP assay was used to determine
the genotype of SNP rs9939506. PCR was carried out in
a DNA thermal cycler (Biometra, Goettingen, Germany)
using the primers: forward: 5'-CAAAGGTGGGCATAG
AGATTG-3'; reverse: 5'-AAGGATTTCTGAGGGACA
CA-3'. PCR was performed after the first denaturation at
95°C for 2 min; each cycle consisted of denaturation at
95°C for 20 sec, annealing at 62°C for 20 sec, and exten-
sion at 72°C for 30 sec. The number of total PCR cycles
was 30. To assess genotyping reproducibility, randomly
selected 20% DNA samples were re-genotyped with
100% concordance.
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) and linkage
disequilibrium (LD) test of SNPs were done by using the
PLINK program [24] and SHEsis. The data were analyzed
using SPSS 20.0 (SPSS Inc., Chicago, IL). Demographics
and clinical measures were reported using descriptive sta-
tistics. Comparisons between genotypes were performed
using the Student’s t-test for continuous variables and χ2
test for categorical variables. Analysis of covariance was
used to examine weight gain at 6 months of risperidone
treatment after controlling for potential confounding
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variables. Further, stepwise multiple regression model
was used to examine the relative predictive value of gene
loci for the risk of weight gain. A p value of less than 0.05
(2-tailed) was used for statistical significance.
Results
Two hundred and fifty first episode, drug naïve schizo-
phrenia patients were enrolled in the study, and 237
(94.8%) completed the follow-up assessment after 6
months of risperione treatment (Table 1). Thirteen pa-
tients withdrew from the study for various reasons be-
fore they reached the 6-month time point (relocation, 5;
transportation difficulty, 6; side effects, 2).
The genotype and allele frequencies of 4 SNPs are
shown in Table 2. No significant deviation was found be-
tween observed values and predicted values from the
Hardy-Weinberg equilibrium (Table 2).
To calculate the extent of linkage disequilibrium (LD)
in pairwise combinations of the 4 SNPs, we calculated
D’ and r2, the normalized LD statistic for all possible
pairs of SNPs. The pairwise D’ and r2 values are shown
in Table 3. Strong LD among the two SNPs (rs9939609
and rs8050136) was observed (r2 > 0.33) (Table 3).
At baseline, body weight and BMI of TT homozygotes
were lower than those of A allele carriers in rs9939609,
and body weight of AA homozygotes was higher than
those of G allele carriers in rs9930506 (p’s < 0.05). After
6 months of risperidone treatment, body weight and
BMI of TT homozygotes were lower than those of A
allele carriers in rs9939609 (p’s <0.01), body weight and
BMI of CC homozygotes were lower than those of A
allele carriers in rs8050136 (p’s < 0.05), and body weight
of AA homozygotes was higher than those of G allele car-
riers in rs9930506 (p’s < 0.05).There was no significant
difference in body weight and BMI between genotypes in
other gene loci (p’s >0.05) (Table 4).
After controlling for age, gender, age of illness onset,
disease duration, weight at baseline and education, weight
gain of TT homozygotes was lower than those of A allele
carriers in rs9939609 (p < 0.01), and weight gain of CC
homozygotes was lower than those of A allele carriers in
rs8050136 (p = 0.01). There was no significant difference
in weight gain at 6 months between genotypes in other
gene loci (p’s >0.05) (Figure 1). Further, stepwise mul-
tiple regression model was developed to identify rele-
vant gene predictors of weight gain at 6 months when
other important potential confounding variables, in-
cluding age, gender, education, disease duration, age of
illness onset, weight at baseline were taken into consid-
eration. Only rs9939609 entered into the regression
model (R2 change = 0.039, df, 1,229, F change = 10.886,
p = 0.001) (Table 5).
Discussion
To our knowledge, this is the first study to examine
the relationship between the four FTO SNPs and
Table 1 Demographic and clinical characteristics of the
study sample
Variables N or Mean ± SD
Male/female (n) 128/109
Smoking(yes/no) 39/198
Age (years) 27.5 ± 7.6
Age of illness onset (years) 25.0 ± 5.0
Disease duration (months) 7.3 ± 4.3
Education (years) 13.2 ± 2.9
Weight (kg) 57.8 ± 8.0
BMI (kg/m2) 20.6 ± 1.9
PANSS-positive 23.0 ± 1.8
PANSS-negative 20.9 ± 1.9
PANSS-general 35.0 ± 3.9
PANSS-total 79.5 ± 4.9
BMI, body mass index; PANSS, the Positive and Negative Syndrome Scale,
including positive symptoms, negative symptoms, general
psychopathology subscales.
Table 2 Genotype and allele frequencies of the FTO gene
and the hardy Weinberg equilibrium test
SNP Genotype n % Allele Frequency HWE
χ2 P
rs9939609 AA 4 1.7 A 0.11
AT 46 19.4 T 0. 89 0.354 0.552
TT 187 78.9
rs8050136 AA 3 1.3 A 0.10
AC 43 18.1 C 0.90 0.107 0.743
CC 191 80.6
rs1421085 CC 3 1.3 C 0.11
CT 45 19.0 T 0.89 0.030 0.862
TT 189 79.7
rs9930506 GG 10 4.2 G 0.17
AG 59 24.9 A 0.83 2.553 0.110
AA 168 70.9
HWE: The Hardy-Weinberg equilibrium test.
Table 3 Linkage disequilibrium analysis of FTO SNPs
D’ rs9939609 rs8050136 rs1421085 rs9930506
r2
rs9939609 ---- 0.977 0.607 0.111
rs8050136 0.855 ---- 0.382 0.038
rs1421085 0.006 0.002 ---- 0.547
rs9930506 0.000 0.000 0.008 ----
The top right is the value of D’, and the bottom left is the value of r2.
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Table 4 Comparison of body weight and BMI between different genotypes
Characteristics rs9939609 rs8050136 rs1421085 rs9930506
AA + AT TT T or x2 P AA + AC CC t or x2 p CC + CT TT t or x2 p GG + AG AA t or x2 p
Male/female (n) 27/23 101/86 0.000 0.999 25/21 103/88 0.003 0.959 25/23 103/86 0.090 0.764 35/34 93/75 0.423 0.516
Age (years) 29.0 ± 7.5 26.9 ± 6.8 −1.819 0.07 29.1 ± 7.7 26.9 ± 6.8 −1.912 0.057 27.8 ± 7.5 27.3 ± 6.9 −0.427 0.67 27.7 ± 7.3 27.2 ± 6.9 −0.487 0.627
Age of illness onset (years) 26.2 ± 5.5 24.7 ± 4.7 1.949 0.053 26.3 ± 5.6 24.7 ± 4.7 1.772 0.81 24.8 ± 5.2 25.1 ± 4.9 −0.393 0.695 24.9 ± 4.8 25.0 ± 5.0 −0.174 0.86
Disease duration (months) 6.6 ± 4.9 7.5 ± 4.2 −1.334 0.183 6.5 ± 4.2 7.6 ± 4.3 −1.517 0.131 7.1 ± 3.9 7.4 ± 4.4 −0.427 0.670 7.5 ± 4.4 7.5 ± 4.3 0.411 0.682
Education (years) 13.3 ± 2.5 13.2 ± 3.0 −0.246 0.806 13.3 ± 2.6 13.2 ± 3.0 −0.296 0.767 13.2 ± 3.0 13.2 ± 2.9 −0.104 0.917 13.6 ± 3.1 13.0 ± 2.9 −1.223 0.223
Baseline
Weight (kg) 63.0 ± 10.8 59.5 ± 10.1 2.14 0.033* 62.6 ± 10.9 59.7 ± 10.2 1.707 0.089 61.7 ± 10.1 59.9 ± 10.4 1.065 0.288 58.2 ± 10.1 61.1 ± 10.4 −2.012 0.045*
BMI(kg/m2) 22.4 ± 3.2 21.2 ± 2.8 2.383 0.020* 22.3 ± 3.3 21.3 ± 2.8 1.955 0.055 22.1 ± 3.0 21.3 ± 2.9 1.637 0.103 21.0 ± 3.0 21.7 ± 2.9 −1.7272 0.085
Six months
Weight (kg) 71.7 ± 10.3 67.0 ± 9.8 2.949 0.004* 71.1 ± 10.4 67.2 ± 9.9 2.354 0.019* 68.9 ± 9.8 67.7 ± 10.1 0.714 0.476 65.8 ± 10.0 68.9 ± 9.984 −2.132 0.034*
BMI (kg/m2) 25.5 ± 3.0 23.9 ± 2.7 3.628 0.000* 25.4 ± 3.0 24.0 ± 2.7 3.009 0.003* 24.7 ± 2.8 24.2 ± 2.8 1.215 0.226 23.8 ± 3.0 24.5 ± 2.7 −1.786 0.075

















antipsychotic-associated weight gain in drug naïve,
Chinese Han patients with first episode schizophrenia.
Our study suggested that SNPs rs9939609 and rs8050136
of FTO gene might play an important role in weight gain
after 6 months of risperidone treatment. Our study did
not find significant relationships between SNPs rs9930506
and rs1421085 of FTO gene and antipsychotic-associated
weight gain.
Our results suggested that A allele in rs9939609 and
rs8050136 could be a risk allele of weight gain in first-
episode schizophrenia; the findings are consistent with
the results from a previous study in a healthy Japanese
human sample [25], but they found no significant differ-
ence in BMI across different medications. Other studies
also found that the FTO gene is associated with obesity
or obesity-related diseases in non-schizophrenia popu-
lations [5,6]. Liu et al. [8] identified positive associations
between SNPs rs9939609 and rs8050136 of FTO gene
and the risk to develop type 2 diabetes in the Chinese
Han population. Ahmad et al. [26] found that the SNP
rs8050136 polymorphism was associated with obesity
and other metabolic problems in healthy US women. Few
studies have investigated the relationship between FTO
SNP polymorphisms and antipsychotic-associated weight
gain with inconsistent findings [27-30]. For example,
Tiwari et al. [31] found that the SNP rs9922047 poly-
morphism of FTO gene was associated with percent
weight gain in patients with schizophrenia; Perez-Iglesias
et al. [28] found the magnitude of weight gain was similar
among 3 genotypes of the SNP rs9939609 of FTO gene in
patients with schizophrenia after 1 year of antipsychotic
treatment.
The FTO gene is the first and most robustly replicated
gene that is related to body weight and fat mass [32,33].
However, the underlying mechanisms remain to be un-
clear. FTO gene is highly expressed in the brain, par-
ticularly in the hypothalamus, which governs energy
balance by regulating appetite and food intake [28].
Furthermore, it has been described that the FTO gene en-
codes a 2-oxoglutarate-dependent nucleic acid demethy-
lase [34,35], which is a transcription coactivator related
to energy homeostasis [34]. The rs9939609 is in the first
intron of FTO gene. Frayling et al. [6] first reported that
rs9939609 is association with obesity-related traits in
both adults and children of European descents. Chang
et al. [16] found that rs9939609 A allele is strongly as-
sociated with obesity and BMI in the Chinese popula-
tion; another study in Chinese and Malays who lived in
Singapore also reported a significant association be-
tween rs9939609 and obesity [17]. For the first time, our
study found that s9939609 is associated with weight gain
after risperidone treatment in patients with schizophrenia.
Our research has some limitations. First, the sample
size is relatively small and larger studies are needed to
confirm our findings. Second, patients on other antipsy-
chotics were not included in the study. Third, there was
lack of a healthy control group. Therefore it is unclear if
the effect sizes of the genetic markers (4 SNPs) in pa-
tients with schizophrenia are the same as in the general
population. Lastly, potential confounding variables that
could contribute to weight gain such as dosage of risper-
idone; environmental factors like physical activity, diet,
employment status, as well as other genetic risk factors
were not measured in the present study. In order to better
understand the effect of genetic factors on antipsychotic-
associated weight gain, future studies should examine
gene-environmental interaction and gene-gene interac-
tion to explore the role of FTO gene polymorphisms in
antipsychotic-associated weight gain.
Conclusion
Our findings suggest that FTO SNP rs9939609 seem to
be related to weight gain after risperidone treatment in
Chinese Han patients with first episode schizophrenia.
Table 5 Multiple regression analysis: rs9939609 predicts
weight gain at 6 months after controlling for age,
gender, education, disease duration, age of illness onset
and weight at baseline
Predictors R2 change df F change P
Step 1: age, gender, education,
disease duration, age of illness
onset, weight at baseline
0.131 6,230 5.782 <0.001
Step 2: rs9939609 0.039 1,229 10.886 0.001
Potential confounding variables including age, gender, education, disease
duration, age of illness onset and weight at baseline were entered first (forced
entry, Step 1); rs9939609, rs8050136, rs1421085 and rs9930506 genes were
considered next (stepwise, Step 2), and rs9939609 gene was the only variable
that entered into the regression model.
Figure 1 Comparison of weight gain after 6 months of
risperidone treatment between different genotypes.
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